{"id":34272,"date":"2018-11-20T08:00:00","date_gmt":"2018-11-20T07:00:00","guid":{"rendered":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/"},"modified":"2018-11-20T08:00:00","modified_gmt":"2018-11-20T07:00:00","slug":"ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/","title":{"rendered":"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II"},"content":{"rendered":"<p> <\/p>\n<p><b>Paris (France), 20 novembre 2018 \u2013\u00a0<\/b>Ipsen (Euronext : IPN ; ADR : IPSEY) et 3BP ont annonc\u00e9 aujourd\u2019hui qu\u2019un premier patient avait \u00e9t\u00e9 trait\u00e9 par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique, le\u00a0177Lu\u2011IPN01087 (anciennement connu sous le nom de 3BP-227), dans le cadre d\u2019une \u00e9tude de phase I\/II. IPN01087 est un compos\u00e9 qui cible les cellules canc\u00e9reuses chez les patients atteints de tumeurs solides avanc\u00e9es avec une expression du r\u00e9cepteur de la neurotensine de sous-type 1 (NTSR1).<br \/>Le principal objectif de cet essai de phase I \u00e0 dose croissante (EUDRACT 2017-001263-20) est d\u2019\u00e9valuer la tol\u00e9rance et l\u2019efficacit\u00e9, ainsi que la posologie optimale de traitement par le radio-isotope administr\u00e9e par voie syst\u00e9mique pour traiter les patients atteints d\u2019une des tumeurs solides exprimant le NTSR1 suivantes\u00a0: ad\u00e9nocarcinome canalaire pancr\u00e9atique, cancer colorectal, cancer gastrique, tumeurs stromales gastro-intestinales, sarcome d\u2019Ewing et carcinome \u00e9pidermo\u00efde de la t\u00eate et du cou.<br \/><b>Le Docteur Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif R&amp;D et Chief Scientific Officer, Ipsen,<\/b>\u00a0a d\u00e9clar\u00e9 :\u00a0<em>\u00ab\u00a0Ipsen s\u2019engage \u00e0 proposer aux patients atteints de cancer une radioth\u00e9rapie syst\u00e9mique innovante en utilisant des m\u00e9dicaments radiopharmaceutiques cibl\u00e9s. Nous sommes heureux d\u2019annoncer les progr\u00e8s accomplis dans le d\u00e9veloppement de IPN01087 dans le cadre de cette \u00e9tude de phase I\/II. Notre approche th\u00e9ranostique cibl\u00e9e, d\u00e9velopp\u00e9e en partenariat avec 3B Pharmaceuticals, offre une nouvelle solution th\u00e9rapeutique encourageante pour r\u00e9pondre aux besoins m\u00e9dicaux non satisfaits li\u00e9s \u00e0 un certain nombre de tumeurs solides.\u00a0\u00bb<\/em><br \/><em>\u00ab\u00a0C\u2019est un grand pas en avant pour IPN01087 et pour 3B Pharmaceuticals\u00a0\u00bb,<\/em>\u00a0a d\u00e9clar\u00e9\u00a0<b>le Docteur Ulrich Reineke, Directeur g\u00e9n\u00e9ral de 3BP<\/b>.\u00a0<em>\u00ab\u00a0Nous sommes ravis que ce compos\u00e9 fasse l\u2019objet d\u2019essais cliniques et nous sommes confiants dans la radioth\u00e9rapie syst\u00e9mique et son potentiel pour am\u00e9liorer la vie des patients.\u00a0\u00bb<\/em><\/p>\n<p><\/p>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[3556],"tags":[],"class_list":["post-34272","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/\",\"name\":\"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-11-20T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/06\/13064320\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/06\/13064320\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II - Global","og_url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/","name":"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II - Global","isPartOf":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#primaryimage"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-11-20T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/communique-de-presse\/ipsen-et-3bp-annoncent-le-traitement-du-premier-patient-par-un-radionucleide-dune-nouvelle-classe-therapeutique-ipn01087-dans-le-cadre-dune-etude-de-phase-i-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen et 3BP annoncent le traitement du premier patient par un radionucl\u00e9ide d\u2019une nouvelle classe th\u00e9rapeutique (IPN01087) dans le cadre d\u2019une \u00e9tude de phase I\/II"}]},{"@type":"WebSite","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization","name":"IPSEN","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/06\/13064320\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/06\/13064320\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/34272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/34272\/revisions"}],"wp:attachment":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/media?parent=34272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/categories?post=34272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/tags?post=34272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}